Inhibikase Therapeutics Return On Asset vs. Net Income
| IKT Stock | USD 3.44 0.20 6.17% |
For Inhibikase Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Inhibikase Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Inhibikase Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Inhibikase Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Inhibikase Therapeutics over time as well as its relative position and ranking within its peers.
Inhibikase |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inhibikase Therapeutics. If investors know Inhibikase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inhibikase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.12) | Revenue Per Share 0.014 | Quarterly Revenue Growth (1.00) | Return On Assets (0.76) | Return On Equity (1.50) |
The market value of Inhibikase Therapeutics is measured differently than its book value, which is the value of Inhibikase that is recorded on the company's balance sheet. Investors also form their own opinion of Inhibikase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Inhibikase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inhibikase Therapeutics' market value can be influenced by many factors that don't directly affect Inhibikase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inhibikase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Inhibikase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inhibikase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Inhibikase Therapeutics Net Income vs. Return On Asset Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Inhibikase Therapeutics's current stock value. Our valuation model uses many indicators to compare Inhibikase Therapeutics value to that of its competitors to determine the firm's financial worth. Inhibikase Therapeutics is rated below average in return on asset category among its peers. It is rated second overall in net income category among its peers . At this time, Inhibikase Therapeutics' Net Loss is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Inhibikase Therapeutics by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Inhibikase Net Income vs. Return On Asset
Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Inhibikase Therapeutics |
| = | -0.76 |
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Inhibikase Therapeutics |
| = | (19.03 M) |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
Inhibikase Net Income Comparison
Inhibikase Therapeutics is currently under evaluation in net income category among its peers.
Inhibikase Therapeutics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Inhibikase Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Inhibikase Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Inhibikase Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Inhibikase Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 877.00 | 833.15 | |
| Net Loss | -13.3 M | -12.6 M | |
| Net Interest Income | 891.2 K | 935.8 K | |
| Operating Income | -20.1 M | -19.1 M | |
| Net Loss | -19.1 M | -18.2 M | |
| Income Before Tax | -19 M | -18.1 M | |
| Total Other Income Expense Net | 1.1 M | 1.1 M | |
| Net Loss | -19 M | -18.1 M | |
| Income Tax Expense | -134 K | -127.3 K | |
| Interest Income | 891.2 K | 531.1 K | |
| Change To Netincome | 2.6 M | 1.6 M | |
| Net Loss | (3.57) | (3.75) | |
| Income Quality | 0.95 | 1.00 | |
| Net Income Per E B T | 1.14 | 1.10 |
Inhibikase Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Inhibikase Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Inhibikase Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Inhibikase Therapeutics' important profitability drivers and their relationship over time.
Use Inhibikase Therapeutics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Inhibikase Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will appreciate offsetting losses from the drop in the long position's value.Inhibikase Therapeutics Pair Trading
Inhibikase Therapeutics Pair Trading Analysis
The ability to find closely correlated positions to Inhibikase Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Inhibikase Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Inhibikase Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Inhibikase Therapeutics to buy it.
The correlation of Inhibikase Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Inhibikase Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Inhibikase Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Inhibikase Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Inhibikase Therapeutics position
In addition to having Inhibikase Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Asset Allocation ETFs Thematic Idea Now
Asset Allocation ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Asset Allocation ETFs theme has 145 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Asset Allocation ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Inhibikase Stock Analysis
When running Inhibikase Therapeutics' price analysis, check to measure Inhibikase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibikase Therapeutics is operating at the current time. Most of Inhibikase Therapeutics' value examination focuses on studying past and present price action to predict the probability of Inhibikase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibikase Therapeutics' price. Additionally, you may evaluate how the addition of Inhibikase Therapeutics to your portfolios can decrease your overall portfolio volatility.